Tonix Pharmaceuticals (TNXP) announced that COO Jessica Morris will present at the 2025 Virtual Investor Summit on March 11, 2025, at 10:30 a.m. ET.
The company's development portfolio highlights include:
- TNX-102 SL for fibromyalgia management, with a PDUFA date of August 15, 2025, and Fast Track designation
- TNX-1300, a Phase 2 biologic with Breakthrough Therapy designation for cocaine intoxication
- TNX-1500 for organ transplant rejection and autoimmune diseases
- TNX-801, a vaccine candidate for mpox
Notable developments include a $34 million DoD contract for developing TNX-4200 antiviral agents. The company operates an infectious disease research facility in Frederick, Md., and markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment through its commercial subsidiary.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.